Welcome to our dedicated page for InfuSystem Holdings SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on InfuSystem Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into InfuSystem Holdings's regulatory disclosures and financial reporting.
InfuSystem Holdings director Ronald T. Hundzinski received a stock option grant covering 24,890 shares of common stock. The option has an exercise price of $8.37 per share, vests on May 12, 2027, and expires on May 12, 2036. It represents a compensation-related award rather than an open-market purchase or sale. Following the reported transactions, Hundzinski holds 5,000 shares of InfuSystem common stock directly.
InfuSystem Holdings director Scott Shuda received a new stock option grant and reported his share holdings. He was granted options for 24,890 shares of common stock at an exercise price of $8.37 per share, expiring on May 12, 2036. The option represents the right to buy 24,890 shares and vests on May 12, 2027.
After these updates, Shuda holds 94,000 shares of common stock directly and 298,383 shares indirectly through Meridian OHC Partners, LP and BlueLine Capital Partners II, over which he has voting and dispositive power. He disclaims beneficial ownership of the shares held by Meridian and BlueLine for purposes of Rule 13d-3.
InfuSystem Holdings, Inc. director John J. Sviokla reported an equity compensation grant and his current shareholdings. He received stock options covering 24,890 shares of common stock at an exercise price of $8.37 per share. These options vest on May 12, 2027 and expire on May 12, 2036, giving him the right to buy shares in the future if conditions are met. The filing also shows he directly holds 10,000 shares of InfuSystem common stock following these transactions.
InfuSystem Holdings, Inc executive vice president and CIO Addam Chupa reported updated holdings and new equity awards. He now directly holds 47,210 shares of common stock, which the footnotes state includes 2,254 shares recently acquired through the company’s Employee Stock Purchase Plan.
On the same date, he received 9,973 restricted stock units that each convert into one share of common stock and 20,777 stock options with an exercise price of $8.37 per share. The options vest in four equal annual installments beginning on May 12, 2027, while the restricted stock units vest in three equal annual installments beginning on the same date.
InfuSystem Holdings director Beverly A. Huss reported an equity compensation grant. She received a stock option for 24,890 shares of common stock, with an exercise price of $8.37 per share. The option vests on May 12, 2027 and expires on May 12, 2036.
Following this grant, Huss holds 4,300 shares of common stock directly, along with the newly awarded options for 24,890 underlying shares. The filing reflects a compensation-related award rather than an open-market purchase or sale.
InfuSystem Holdings director Paul Andrew Gendron received a new stock option grant as part of his compensation. He was granted options to acquire 24,890 shares of common stock at an exercise price of $8.37 per share, expiring in 2036. These options vest on May 12, 2027. Following the reported transactions, he directly holds 70,000 shares of InfuSystem common stock, indicating this filing reflects equity-based incentives rather than open-market buying or selling.
InfuSystem Holdings Executive VP and CFO Barry G. Steele reported new equity awards. He received 17,121 restricted stock units that convert into common stock on a one-for-one basis and 35,668 stock options with an exercise price of $8.37 per share. The options vest in four equal annual installments beginning on May 12, 2027, while the RSUs vest in three equal annual installments starting the same date. After these awards, he directly holds 96,590 shares of common stock.
InfuSystem Holdings President and CEO Carrie Lachance reported new equity awards and updated holdings. She received a grant of 29,816 restricted stock units, which convert into common stock on a one-for-one basis and vest in three equal annual installments beginning on May 12, 2027. She also received a stock option covering 62,117 shares of common stock at an exercise price of $8.37 per share, expiring on May 12, 2036, vesting in four equal annual installments starting May 12, 2027. Following these awards, she directly holds 238,123 shares of InfuSystem common stock. These actions reflect compensation-related grants rather than open-market purchases or sales.
InfuSystem Holdings, Inc executive Jerod Funke, EVP–Chief HR Officer, reported new equity compensation awards. He received 11,478 restricted stock units, which each convert into one share of common stock and vest in three equal annual installments beginning on May 12, 2027.
He was also granted a stock option for 23,913 shares of common stock at an exercise price of $8.37 per share, vesting in four equal annual installments beginning May 12, 2027 and expiring on May 12, 2036. Following these awards, he holds 18,662 shares of common stock directly, alongside the new unvested RSUs and options.
InfuSystem Holdings director Kenneth D. Eichenbaum reported a new stock option grant tied to the company’s common stock. He received options covering 24,890 shares at an exercise price of $8.37 per share, recorded as a grant or award acquisition.
The option vests on May 12, 2027 and expires on May 12, 2036, giving him the right to buy InfuSystem common shares at the fixed exercise price once vested. Following these entries, he is shown holding 6,000 shares of common stock directly.